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Abstract
With recent improvement in hardware and software techniques, magnetic resonance angiography (MRA) has
undergone significant changes in technique and approach. The advent of 3.0 T magnets has allowed reduction in
exogenous contrast dose without compromising overall image quality. The use of novel intravascular contrast
agents substantially increases the image windows and decreases contrast dose. Additionally, the lower risk and
cost in non-contrast enhanced (NCE) MRA has sparked renewed interest in these methods. This article discusses
the current state of both contrast-enhanced (CE) and NCE-MRA. New CE-MRA methods take advantage of dose
reduction at 3.0 T, novel contrast agents, and parallel imaging methods. The risks of gadolinium-based contrast
media, and the NCE-MRA methods of time-of-flight, steady-state free precession, and phase contrast are discussed.
Introduction
Clinical applications for Magnetic Resonance Angiogra-
phy (MRA) are rapidly expanding as technological
advances in both hardware and imaging techniques over-
come previous limitations, and the risks from intravenous
contrast agents and repeated ionizing radiation exposure
become more salient for the clinician and patient [1].
Magnetic resonance imaging (MRI) has the advantage of
relying on the intrinsic magnetic properties of body tis-
sues and blood in an external magnetic field to produce
an image, without the need of ionizing radiation or
nephrotoxic contrast agents. With the increasing avail-
ability and use of 3.0-Tesla (T) magnets, which received
FDA approval in 2002, and optimized pulse sequences,
high-quality images with excellent spatial resolution can
be obtained in shorter scan times with smaller or no
injections of contrast agents. In this manuscript we will
review recent developments in (1) performing MRA at
3.0T, including “low-dose” contrast-enhanced (CE) MRA,
and (2) new non-CE (NCE) MRA techniques.
MRA at 3.0T
At 3.0T, twice as many protons are aligned with the
magnetic field as compared to 1.5T, resulting in a theo-
retically doubled signal-to-noise ratio (SNR). This gain
in SNR can be taken advantage of to increase the spatial
resolution, decrease acquisition time, or a combination
of the two to achieve the same SNR characteristics as
1.5T in less time. Increased spatial resolution allows for
improved visibility of lesions, and faster acquisition
times helps reduce motion artifact and decrease breath-
holding requirements [2]. Additionally, the vessel to
background contrast enhancemnt effects of gadolinium
( G d )a r ee v e nm o r ep r o n o u n c e da t3 . 0 T ,p r o d u c i n g
higher contrast images and therefore requiring lower
doses of Gd-based agents to achieve similar image qual-
ity found at lower field strengths (Figure 1) [3].
Typically, CE-MRA techniques are used more often
than NCE-MRA techniques. Advantages of CE-MRA
relative to other MRA techniques, such as time-of-flight
(TOF) and phase-contrast (PC), include shorter acquisi-
tion times, improved anatomical coverage, and decreased
susceptibility to artifacts caused by blood flow and pulsa-
tility. To avoid combined arterial and venous enhance-
ment, shorter acquisition times are necessary to obtain
purely “arterial” p h a s ei m a g e s .T h i sc a nb ed o n eu s i n g
acquisitions with a parallel imaging or time-resolved
techniques. At 3.0T, the gain in SNR can allow higher
acceleration factors in parallel imaging to decrease scan
times and improve spatial resolution even further [3-5].
While 3.0T opens many possibilities for the future of
MRA, it also carries with it a new set of clinical and
technological problems that need to be addressed before
gaining widespread use. Pulse sequences that have been
optimized for 1.5T may need to be adjusted for 3.0T
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strength increases energy deposition in the patient and
field inhomogeneity, as discussed below.
Contrast-enhanced MRA at 3.0T
Although gadolinium based agents have an excellent safety
record, reports linking gadolinium to nephrogenic sys-
temic fibrosis have sparked renewed interest in “low-dose”
CE-MRA and NCE-MRA [6-8]. In addition, low-doses of
contrast also help reduce the costs of performing CE-
MRA. Gadolinium chelates are paramagnetic compounds
that shorten T1 and T2 relaxation times by disrupting
spin-lattice and spin-spin interactions respectively. These
effects of Gd on body tissues are relatively unaffected by
increased magnetic field strength. Thus, although body tis-
sue T1 relaxation times are increased at 3.0T, the T1
relaxation times of Gd-contrast agents remain relatively
unchanged at higher magnetic field strengths. This results
in noticeable increases in the blood pool-to-background
contrast-to-noise ratio (CNR) compared to 1.5T. The
increase in CNR at 3.0T can be used to improve the image
quality using the same amount of contrast or to decrease
the amount of IV contrast injected compared to a similar
scan at 1.5T (Figure 2) [5,9]. Tomasian et al. recently
demonstrated that for 3.0T MRA of the supraaortic
arteries, a contrast dose reduction from 0.15 to 0.05
mmol/kg did not compromise image quality, acquisition
speed, or spatial resolution [5]. Arterial occlusive disease
was detected nearly equally between the two readers, with
no significant difference in arterial definition scores.
CE-MRA has been established as a non-invasive alter-
native to conventional angiography in evaluating periph-
eral vascular disease [10-12] and can be an alternative to
CTA for the diagnosis of acute pulmonary embolism
[13]. Lower-extremity MRA is typically associated with
the highest contrast dose protocols of all MR imaging
techniques, often requiring a double-dose (0.2 mmol/kg)
or more of Gd-contrast to be administered [14]. It has
been shown that the amount of Gd-contrast needed at
3.0T for lower extremity MRA can be reduced up to
one-third of that used at 1.5T (i.e. from 0.3 mmol/kg to
0.1 mmol/kg) [15]. The resulting images at lower con-
trast doses had better arterial definition than high-dose
images, presumably due to lower residual background
signal from the initial contrast injection and less venous
contamination [16].
Renal CE-MRA quality at 3.0T has also been evaluated
with low-dose Gd. Attenberger et al. demonstrated equal
image quality for evaluation of the renal arteries com-
paring 0.1 mmol/kg of gadobenate dimeglumine at 3.0T
with 0.2 mmol/kg of gadobutrol at 1.5T [17]. Kramer et
al. compared low-dose (0.1 mmol/kg) gadopentetate
dimeglumine at 3.0T with conventional digital subtrac-
tion angiography (DSA) for evaluation of renal artery
stenosis in 29 patients, yielding good to excellent quality
images with sensitivity and specificity of 94% and 96%
respectively [4]. These findings suggest that at 3.0T, the
contrast dose in current practice is likely higher than
needed, and can be lowered without negatively impact-
ing spatial resolution or overall image quality.
Current CE-MRA techniques using conventional Gd-
contrast agents are limited by the need to acquire images
relatively quickly during the first pass of contrast material
through the vessels of interest. Newer, intravascular Gd-
based contrast agents can help overcome these limita-
tions. Gadofosveset trisodium, a protein-binding intravas-
cular contrast agent that has recently obtained FDA
approval for use in CE-MRA of the aorto-iliac segments,
differs from other gadolinium-based contrast media by
Figure 1 CE MRA at 1.5 T and 3.0 T. 56 year-old male with celiac
(closed arrow) and superior mesenteric artery (open arrow)
dissections. CE MRA at 1.5 T (A) has lower spatial resolution and
contrast-to-noise-ratio than at 3.0 T (B).
Figure 2 Low dose CE MRA. Contrast-enhanced renal MRA at 3.0T
using 0.1 mmol/kg of gadobenate dimeglumine. Image quality and
vessel conspicuity are excellent even with a relatively low dose of
intravenous contrast.
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higher relaxivity [18]. Gadofosveset requires smaller total
amounts of contrast (Figure 3) and extends the imaging
windows up to 60 minutes or more. Images can then be
obtained during the steady-state phase after the adminis-
tration of IV contrast, permitting longer scan times to
acquire very high spatial resolution CE-MRA images. A
study by Klessen et al. [18] demonstrated that 10 mL of
Gadofosveset trisodium produced qualitatively better
images with higher arterial contrast compared to 30 mL
of gadopentetate dimeglumine. Further optimization of
the injection protocol is speculated to further improve
the results found in this study.
Parallel imaging at 3.0T
Parallel imaging further enhances the benefits of 3.0T
by undersampling the area of interest as a tradeoff for
increased image acquisition speed. Parallel imaging has
been applied to CE-MRA to reduce scan time and
improve spatial resolution by improving anatomic cov-
erage and removing aliasing artifact with the use of
multiple channel coils (Figu r e4 )[ 1 9 ] .T h ei n d i v i d u a l
coils, which have varying spatial sensitivities, are used
to simultaneously receive MR signal following a single
radiofrequency (RF) pulse. This permits faster image
acquisition with fewer motion artifacts, less RF excita-
tions pulses, and lower energy burden for the patient,
but some aliasing is present due to missing k-space
data as a result of undersampling. In a study by
Fenchel et al. [20], high-quality CE-MRA with inte-
grated parallel acquisition technique (iPAT2) and sin-
gle contrast injection has been shown to produce
adequate image quality of the entire arterial vascula-
ture with acceptable SNR and CNR values for whole-
body applications, in less than 60 seconds. Parallel
imaging can also increase the anatomical coverage.
Lum, et al. [21] recently demonstrated the use of a
two-dimensional autocalibrating parallel imaging tech-
nique (2D-ARC) to increase the coverage for abdom-
inal CE-MRA. Subjective image quality and vessel
conspicuity were graded for healthy volunteers and
patients with suspected renovascular disease for MRA
with and without 2D-ARC. The results demonstrated
equivalent image quality in both methods, with the
benefit of a 3.5-fold increase in imaging volume and
complete abdominal coverage within the same acquisi-
tion time for 2D-ARC MRA. This same technique can
also be used to perform high resolution, whole chest
MRA in a shorter time, which is important in the eva-
luation of patients suspected of having pulmonary
embolism or who are short of breath (Figures 5, 6).
Limitations and safety concerns for CE-MRA at 3.0T
The stronger magnetic field at 3.0T results in significant
challenges and limitations that are yet to be fully over-
come. Constructive and destructive interference due to RF
field inhomogeneity and increased Specific Absorption
Rate (SAR) are major concerns when imaging at 3.0T.
Figure 3 CE MRA with intravascular contrast agent. (A) First-pass
and (B) steady-state multiplanar reformatted images from contrast-
enhanced MRA done with 0.03 mmol/kg of gadofosveset trisodium
in a 25 year-old male with a right lower lobe segmental pulmonary
embolus (arrow). Even during the steady-state there is substantial
intravascular signal to accurately diagnose the pulmonary embolism.
Figure 4 Large field of view CE MRA using parallel imaging.
Parallel imaging and a 32-channel coil were used to scan the entire
aorta from the aortic root to beyond the bifurcation in this 49 year-
old male with prior ascending aortic dissection repair (arrowheads)
and residual dissection in the descending aorta (open arrows = true
lumen; closed arrows = partially thrombosed false lumen).
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ence and loss of complete anatomic coverage within the
image field. At 3.0T, the resonance frequency of protons
in water is 128 MHz, double the value in a 1.5T system,
which means that the radiofrequency wavelength is
halved from 52 cm to 26 cm. This shortened wavelength
can span the dimensions of the field of view for abdom-
inal and pelvic imaging, occurring more frequently in
persons with a large body habitus [22]. As two RF waves
overlap in the imaging field, constructive or destructive
interference can result in areas of brightening or dar-
kening respectively. A similar artifact can occur in per-
sons with large amount of fluid in their abdomen (eg.
ascites or pregnancy). Electrical current circulates within
the fluid under the strong magnetic field and interferes
with the RF field pulses resulting in interference [23].
Advances in coil design, such as multicoil transmit body
coils, can suppress eddy currents and improve RF field
homogeniety at higher field strengths [24]. In addition
to improved coil design, new pulse sequences such as
three-dimensional tailored RF pulses have been shown
to improve homogeneity of the radiofrequency excita-
tion[25].
RF pulses transfer energy to protons within the patient
and ultimately generate heat as a byproduct of energy
release. Heat produced within the patient can have det-
rimental physiologic effects and is carefully monitored
within the imaging setting, with current limits of total
body heating set by the FDA at 4 W/kg for the whole
body over a 15 minute period [26,27]. SAR provides an
estimate for the energy deposited in the tissue by the RF
pulse and increases with the square of the resonance
frequency. At 3.0T, the resonance frequency is double
that of a 1.5T system, and thus the SAR is increased
fourfold [2]. Modified pulse sequences, acquisition tech-
niques, and hardware designs are being developed to aid
in management of the increased SAR at higher fields.
The use of parallel imaging also provides an important
solution to this problem, as the multiple detector coils
used to simultaneously encode a larger anatomic region
serve to both decrease acquisition time and decrease the
number of RF pulses needed to acquire an image.
Non Contrast-Enhanced Magnetic Resonance
Angiography (NCE-MRA)
The widespread use NCE-MRA has been limited by pro-
longed acquisition times and motion artifacts that favor
CE-MRA. However, several factors have contributed to
a renewed interest in NCE-MRA methods, including
improvements in MR hardware and software and con-
cerns over the safety of gadolinium-based contrast in
high-risk patient groups. The latter is particularly con-
cerning, as patients with moderate to severe renal insuf-
ficiency and vascular or metabolic disorders are at risk
Figure 5 Rapid whole chest CE MRA using parallel imaging.
Contrast-enhanced pulmonary MRA in 47 year-old male with
pulmonary artery hypertension and a pulmonary arteriovenous
malformation (arrow). The use of two-dimensional parallel imaging
enables the scan time to be reduced to 16 seconds while
maintaining whole chest coverage. Imaging at 3.0T increases the
contrast-to-noise ratio, even when only using 15 mL of gadobenate
dimeglumine as in this case.
Figure 6 Rapid whole chest CE MRA using parallel imaging.
The use of parallel imaging to reduce scan time is particularly
important in patients who have difficulty holding their breath. This
contrast-enhanced pulmonary MRA is from a 42 year-old female
with primary pulmonary artery hypertension who requires the use
of oxygen. In this case the scan time was 16 seconds.
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ing disease of nephrogenic systemic fibrosis (NSF) [6-8].
A recent meta-analysis by Agarwal et al. [28] identified
the odds of developing NSF were 27 times greater in
patients with chronic kidney disease (N = 79/1393,
5.7%) exposed to gadolinium compared to control sub-
jects with chronic kidney disease (N = 3/2953, 0.1%)
who did not receive gadolinium. This poses a significant
imaging challenge as metabolic syndrome, diabetes and
renal disease continue to afflict a larger percentage of
the population each year [29]. Also, situations may
occur where NCE-MRA is preferred due to difficult IV
access or contraindication of IV contrast material. High-
resolution CE-MRA usually requires a large bore IV
catheter that may be difficult to place in patients who
are obese or with poor veins, and IV contrast agents are
usually not given during in pregnancy due to teratogenic
effects observed in animal studies.
NCE-MRA has been available since the beginning of
MR imaging and is routinely used for intracranial ima-
ging. It has also been validated for use in coronary, thor-
acic, renal and peripheral vascular disease [30]. In a
recent review, Provenzale et al. [31] found similar diag-
nostic quality in MRI combined with MRA compared to
CTA for carotid and vertebral dissection without clear
superiority of either method. TOF MRA has also been
compared to computed tomography angiography (CTA)
and digital subtraction angiography (DSA) in following
treated cerebral aneurysms, and has high sensitivity in
detecting residual flow within the aneurysm [32].
Coronary MRA has been validated primarily at 1.5T
[33-37], but its clinical use has been limited by limita-
tions in visualizing distal segment and small branch dis-
ease [38]. and the widespread introduction of coronary
CTA. However, coronary MRA still has a role in the eva-
luation of anomalous coronary artery origins (Figure 7),
particularly in pediatric patients. In addition, coronary
MRA may have a role in evaluating patients with signifi-
cant stenosis in coronary artery segments with moderate
to severe calcification, due to increased artifact and diffi-
culty visualizing stenosis with CTA in patients with high
calcium scores [39]. Additionally, at 3.0T the improved
SNR can increase visibility of distal coronary artery seg-
ments and shorter imaging time can improve image
sharpness [40]. Due to the increased artifacts with SSFP
sequences at 3.0T, contrast-enhanced coronary MRA
methods have been revisited with promising initial results
[41-45].
Time-of-Flight MRA
Time-of-flight (TOF) is the most commonly used NCE
MRA technique, especially for peripheral and intracra-
nial applications. TOF relies on the suppression of the
background signal by rapid slice-selective radiofrequency
excitation pulses that saturate the signal from stationary
tissue, resulting in suppressed background signal [30,46].
Because the venous signal could potentially obscure the
visualization of the adjacent arteries, the venous flow is
usually selectively suppressed by applying a saturation
band on the venous side of the imaging slice to null the
signal as it enters the slice being imaged. This same
principle can be applied to the diaphragm during
respiration and the heart during the cardiac cycle. In tis-
sue planes with high flow velocity, the incoming blood
will be free of the excitation pulse that saturates the
background tissues resulting in strong signal intensity.
Slow blood flow or stasis, retrograde filling, tortuous
vessels, or vessels in the same plane as the image slice
result in saturation of the blood flow in the image
volume and poor vessel visualization.
TOF acquisitions can be performed using 2D or 3D
sampling, with 3D TOF being most commonly used for
intracranial vasculature due to the tortuous nature of
the arterial tree, tendency for flow within the imaging
plane, and need for high spatial resolution [46]. 2D TOF
angiography is used more often clinically in the evalua-
tion of the carotid arteries (Figure 8) and peripheral vas-
culature (Figure 9), which is oriented orthogonal to the
imaging plane [47]. While the saturation of protons
within the in-plane vessels is the greatest limitation of
T O F ,i tc a nb eo v e r c o m eb yt h eu s eo fp r o g r e s s i v e l y
increasing flip angles through the slab to compensate
for the saturation of blood flowing into the slab [48],
multiple overlapping thin slab acquisition (MOTSA),
which acquires the image volume as multiple thin 3D
slabs and has less signal saturation than in a single-
volume 3D acquisition [49].
ECG-gating has been successfully applied to CE-MRA
techniques in the thoracic aorta, where cardiac motion
can result in blurring of the vessel wall in the ascending
portion of the aorta [50]. For imaging the peripheral
arteries, where blood flow depends on the phase of the
cardiac cycle, systolic gating can be used to time the
image acquisition during peak blood flow [30]. Lanzman
et al. [51]recently describe the use of a promising novel
ECG-gated 3D NCE-MRA technique in patients with
peripheral artery disease, showing adequate image qual-
ity and disclosure of significant arterial stenoses in the
lower extremities without the need for exogenous con-
trast media.
Steady-State Free Precession MRA
Balanced steady-state free precession (SSFP) techniques
are popular for NCE MRA because image contrast is
determined by T2/T1 ratios, which leads to inherently
bright blood images with little dependence upon blood
inflow [30]. Both arteries and veins have bright signal
with SSFP MRA, which makes this technique well suited
for thoracic MRA applications (Figure 10) where the
vessels are larger and where evaluation of both arterial
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heart disease). In clinical scenarios where venous signal
may interfere with the interpretation of the MRA (i.e.
renal MRA), venous inflow suppression techniques can
be applied to SSFP MRA techniques to obtain purely
arterial MRA images.
In a retrospective analysis by François et al. [52] of 23
patients who underwent both CE-MRA and 3D SSFP of
the thoracic aorta, measurement of the aortic diameter was
essentially equal between the two methods with notably
superior visualization of the aortic root using 3D SSFP. A
separate study compared CE-MRA to 3D SSFP for the eva-
luation of pulmonary veins (PV) prior to radiofrequency
ablation surgery, and the 3D SSFP images demonstrated
accurate PV diameter measurements with superior SNR
and CNR [53]. A study by Krishnam et al. [54] demon-
strated that free-breathing ECG-gated SSFP MRA of the
thoracic aorta had equal diagnostic sensitivity and specifi-
city compared to CE-MRA in 50 patients with suspected
thoracic aorta disease. Independent qualitative and quanti-
tative image analysis showed both techniques providing
excellent visibility grades of all aortic segments. SSFP MRA
demonstrated better visibility of the aortic root and had
higher SNR and CNR values for all segments, while allow-
ing the patient to breathe freely during imaging.
3D SSFP MRA has also been applied to the evaluation of
the renal arteries. Maki, et al. [55]compared 3D SSFP
MRA to CE-MRA at 1.5T in 40 patients and showed that
3D SSFP MRA had a sensitivity of 100% and specificity of
84%. Similarly, Wyttenbach, et al. [56] evaluated 53
patients suspected of renal artery stenosis with 3D SSFP
and CE-MRA at 1.5T, with 3D SSFP MRA having a sensi-
tivity and specificty of 100% and 84%, respectively. A study
by Lanzman et al. [57] compared the image quality and
visibility of renal arteries at 1.5T and 3.0T and demon-
strated a significant gain in SNR and CNR at 3.0T of
13-16% and 16-23% respectively, with the greatest
improvement of mean image quality at the segmental
artery branches. The gain, while significant, is less than
expected by the theoretically doubling of SNR anticipated
at 3.0T due to SSFP relying on contrast from T2/T1 ratio.
Arterial spin labeling (ASL) is a technique that can be
combined with SSFP to enhance image quality through
Figure 7 Coronary MRA with 3D steady-state free precession. The left main coronary artery (open arrow) arises from the right coronary
artery (closed arrow) and courses between the pulmonary artery and aorta (inset). LV = left ventricle; RV = right ventricle; PA = pulmonary
artery; Ao = aorta.
Figure 8 2D time-of-flight MRA of the carotid arteries. (A) Axial
source image with excellent vascular signal in the carotid (arrows)
and vertebral (arrowheads) arteries. (B) Maximum intensity projection
image of the left carotid (arrows) and vertebral (arrowheads) arteries.
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upstream of the imaging field are “tagged” with an
inversion pulse to provide contrast. Background tissue
can be suppressed by subtracting the untagged image
from the tagged blood image in two acquisitions [58] or
by applying a spatially nonselective tag pulse of the
entire imaging field in addition to the tag pulse applied
to the arteries of interest in a single acquisition [30].
ASL with SSFP provides bright-blood, venous-free
images with high SNR especially suited for carotid and
renal artery imaging (Figure 11) due to decreased sensi-
tivity to flow artifacts [30]. The complex vasculature of
the aorta relative to the renal arteries is well visualized
in this technique, and initial clinical experience has
shown comparable results to CE-MRA in both healthy
volunteers and patients with renal artery stenosis
(Figure 12) [59,60]. Using this type of sequence in 67
patients suspectec of renal artery stenosis, Glockner
et al. [61] found that SSFP provided diagnostic images
in most cases, but having a higher incidence of false
positive and negative results compared to CE-MRA.
Figure 9 2D time-of-flight MRA runoff. 2D time-of-flight MRA of
the pelvis, thighs, and calves in a patient with bilateral lower
extremity claudication due to occlusion of the superficial femoral
arteries bilaterally. Flow to the runoff vessels in the calves (ellipses)
is through collateral arteries (open arrows) in the thighs arising from
the profunda femoris arteries.
Figure 10 SSFP thoracic MRA. Non-contrast-enhanced SSFP MRA
in a patient with a saccular aortic arch aneurysm (arrow).
Figure 11 SSFP renal MRA. (A) Non-contrast-enhanced, inflow
prepared, inversion recovery SSFP MRA and (B) contrast-enhanced
MRA in a patient with two right renal arteries (closed arrow = main
renal artery; open arrow = accessory renal artery). Interestingly, the
segmental renal artery branches (arrowheads) are better seen with
SSFP MRA than with contrast enhanced MRA.
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blood in the imaging plane with tagged blood. In per-
ipheral arteries with slower flow, the inflow of tagged
blood can approach the T1 of the surrounding tissues,
thus eliminating the tagging effect. This can be partially
overcome by the multiple, thinner-slab acquisitions, but
at the expense of longer imaging times.
Phase-Contrast MRA
Phase-Contrast (PC) MRA generates an image by apply-
ing a bipolar velocity-encoding gradient during the pulse
sequence twice in opposing directions, which results in a
net phase change of zero in stationary tissues while
applying a phase change in moving blood, producing a
signal. Signal strength is proportional to the velocity of
moving blood, and the strength of the bipolar flow
encoding gradient, which is prescribed by setting the
Velocity Encoding (Venc) value. The Venc describes the
maximum velocity that can be accurately encoded with-
out aliasing, similar to Doppler velocity measurement.
Thus, phase-contrast MRA provides anatomic images of
vessels, in addition to hemodynamic data, about flow,
unlike TOF and CE-MRA techniques. The intravascular
signal loss on 3D PC MRA at and distal to a hemodyna-
mically significant stenosis (Figure 13) is due to intra-
voxel phase dispersion related to turbulent flow, and can
be used to estimate the hemodynamic significance of ste-
noses [62]. PC MRA can be used to identify the direction
and velocity of flow, and has better background suppres-
sion compared to TOF. Its use is limited by longer image
acquisition times and higher sensitivity to changes in
velocity and magnitude of blood flow during the cardiac
cycle [63]. At 3.0T, although there is not increased accu-
racy of flow measurements compared to 1.5T, there is
greater signal and less noise measured for a given VENC.
This allows VENC to be increased, reducing aliasing arti-
facts in regions of higher flow without increasing overall
image noise to unacceptable levels [64].
Traditionally, PC MRA was performed with three-
directional velocity encoding without any temporal infor-
mation to obtain a “complex-difference” MR angiogram.
With this approach, each acquisition was repeated three
times with a different velocity-compensation direction
and once without flow compensation. Because four
acquisitions are needed for 3D PC MRA, the scan times
are long and the imaging volume is limited. Parallel ima-
ging techniques [65] and 3D radial undersampling [66],
or Vastly undersampled Isotropic Projection Reconstruc-
tion (VIPR), have been used to reduce scan time without
compromising coverage or resolution. In addition, these
image acquisition acceleration techniques have enabled
the acquisition of temporal information in addition to
the standard 3D PC MRA acquisition, resulting in four-
dimensional (4D = three-dimensional spatial encoding,
three-directional velocity encoding, and time) PC MRA
for a variety of vascular applications. While these newer
4D PC MRA sequences can be used for NCE MRA, the
future direction of these techniques lies in the additional
hemodynamic information provided. In contrast to con-
ventional two-dimensional (2D) PC MRA, where the ves-
sel of interest must be known prior to scanning and the
image plane must be prescribed at the scanner during the
examination, 4D PC MRA techniques permit the post
priori evaluation of flow velocities of any vessel within
the imaging volume from the same acquisition. In addi-
tion, the 4D PC MRA techniques can be used to qualita-
tively evaluate the complex flow patterns within the
cardiovascular system (Figure 14) [65,67-69] and calcu-
late various hemodynamic parameters non-invasively,
including pressure gradients [70,71,61], wall shear stress,
and oscillatory stress index [68,72]. Implementation of
these techniques into clinical routine is currently limited
by our ability to process and interpret the large amount
of data generated by these sequences.
Conclusions
In summary, recent improvements in MRI hardware and
software have lead to dramatic changes in the techni-
ques used for MRA. The greater use of 3.0T scanners
for MRA combined with improved parallel imaging
methods have brought about a paradigm shift in CE-
MRA toward a “less is more” approach. Further
Figure 12 SSFP renal transplant MRA. (A) Non-contrast-enhanced,
inflow prepared, inversion recovery SSFP MRA, (B) contrast-
enhanced MRA, and (C) digital subtraction angiography in a patient
with renal transplant artery stenosis (closed arrow). A stenosis is also
present in the common iliac artery (open arrow).
Figure 13 3D phase contrast MRA. (A) Contrast-enhanced MRA,
(B) 3D phase contrast (PC) MRA, and (C) digital subtraction
angiography in a patient with right renal artery stenosis (arrow). The
signal void on the 3D PC MRA indicates that the stenosis is
hemodynamically significant. The pressure gradient across the
stenosis at catheter angiography was 18 mmHg.
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been made possible with the availability of novel intra-
vascular contrast agents. The other recent major devel-
opment in MRA has been the renewed use of NCE-
MRA methods. Although NCE-MRA methods still
require longer scan times than CE-MRA methods, they
do offer several advantages over CE-MRA, including
reduced risk to patients and lower costs. Interestingly,
phase-contrast NCE-MRA methods offer the potential
to provide additional hemodynamic information that
currently is obtained using invasive methods.
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